Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin vaccine - DynPort

Next Previous
Drug Profile

Botulinum toxin vaccine - DynPort

Alternative Names: Botulism vaccine - DynPort; rBV A/B; recombinant botulinum neurotoxin vaccine; Recombinant botulinum vaccine A/B

Latest Information Update: 17 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DynPort Vaccine Company LLC; United States Army Medical Research Institute of Infectious Diseases
  • Developer DynPort Vaccine Company
  • Class Bacterial vaccines
  • Mechanism of Action Botulinum toxin inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Botulism

Most Recent Events

  • 17 Apr 2021 No development reported - Phase-II for Botulism (Prevention) in USA (IM) (DynPort Vaccine Compnay pipeline, April 2021)
  • 04 Dec 2018 DynPort withdraws a phase III trial in healthy volunteers in Botulism (Prevention) in USA, prior to enrolment (IM) (NCT01940315)
  • 24 Oct 2018 DynPort plans to re-initiate a phase III trial in healthy volunteers in Botulism (Prevention) in USA (IM) (NCT01940315)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top